값Q4, 24Q4, 25TTM판매비·일반관리비———연구개발———영업 이익———비영업 수익, 합계———이자비용(자본화한 이자 차감 후)———이자비용을 제외한 비영업 수익———비정상 수입/지출———세전소득———지분법 손익———세금———비지배 지분———세후 기타 수익/비용———중단된 사업 부문 제외 순이익———중단된 사업———순이익———희석보정———우선배당———보통주주에게 귀속되는 희석 순이익———주당 순이익(기본 EPS)———희석 주당 순이익 (희석 EPS)———평균 발행주식수———희석주식수———EBITDA———EBIT———매출원가———기타 매출원가———감가상각 및 무형자산 상각 (현금흐름)———
Evogene Ltd. - Ordinary Shares
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.